RSNT BioPharm Inc. is a drug delivery technology company dedicated to transforming the therapeutic landscape through intelligent, patient-friendly, and scalable platform solutions. Our proprietary delivery technologies are engineered to improve treatment accessibility, reduce formulation complexity, and maximize commercial viability across therapeutic categories.
We are advancing cost-effective, modular systems designed to support the efficient delivery of biologics, peptides, and small molecules—across oral, injectable, mucosal, and inhalation routes. Every formulation we develop is optimized for compliance, convenience, and manufacturability at scale.
At RSNT BioPharm, we envision a future where innovative delivery platforms enable therapies to reach patients in ways that are safer, simpler, and more accessible. Our systems are purpose-built to overcome the limitations of traditional drug formats—enhancing performance while reducing cost and complexity. Through platform-driven innovation, we aim to:
Our mission is to develop and commercialize differentiated drug delivery technologies that:
We create technology platforms that solve real, unmet formulation and delivery problems.
Our designs prioritize convenience, usability, and clinical relevance—driving better adherence and health outcomes.
Scientific rigor and pharmaceutical quality systems guide every development milestone.
Our platforms are built with scalability in mind—from early-stage feasibility through global launch.
We co-create solutions with biotech and pharma partners, unlocking mutual value from clinical translation to commercialization.
RSNT BioPharm’s proprietary drug delivery platforms are designed for multi-route flexibility, enhanced compliance, and streamlined development. These platform technologies are compatible with a wide range of therapeutic classes and are ready to support your next formulation challenge.
Key Highlights :Enabling oral or non-invasive delivery of therapeutic peptides and combination therapies
Improving patient adherence in chronic conditions through long-acting and non-oral formats
Precision delivery of proteins and immune modulators via targeted or mucosal approaches
Enhancing tolerability and real-world usability for difficult-to-formulate agents
Unlocking potential for nucleic acid and protein therapeutics through adaptable delivery platforms
Submitted
filings in progress
licensing and co-development
Assessments Completed
Founder & CEO
Raj Thota is a seasoned biopharmaceutical executive and global CMC strategist with over three decades of experience in formulation development, process design, and technology transfer. As the Founder and CEO of RSNT BioPharm Inc., Raj leads the company’s mission to revolutionize drug delivery through platform innovation, manufacturing scalability, and clinical impact.
Over the course of his career, Raj has overseen the development, optimization, and launch of more than 150 drug products, including over 30 complex dosage forms. His expertise spans:Raj has held senior leadership roles at Pharnext S.A., Par Pharmaceutical (Endo), Perrigo, Patheon (Thermo Fisher Scientific), and Frontida BioPharm (Adare Pharma), where he led cross-functional teams in CMC development, global technical operations, manufacturing, and site leadership. His proven ability to blend technical depth with executional excellence has made him a trusted leader in driving speed-to-market, cost control, and quality-by-design principles across programs. Raj holds an MBA, a MS in Pharmaceutical Technology, and advanced certifications in Lean Six Sigma and Global Regulatory Affairs. He brings to RSNT BioPharm the rare combination of hands-on formulation & process leadership and strategic commercialization insight—positioning the company as a premier platform innovator in next-generation drug delivery
